Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?

Background: Despite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), for treating chronic myeloid leukemia (CML), a substantial proportion of patients' treatments fail.

Aim: This study investigates the correlation between patient adherence and failure of TKIs' treatment in a follow-up study.

Methods: This is a follow-up study of a new cohort of CML patients.